Kwak SH, Han KA, Kim KS, Yu JM, et al. Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomised, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 2023 Mar 5. doi: 10.1111/dom.15046.
PMID: 36872067